Despite wide-spread use of disposable bioreactors, there is a lack of well-established scale-down model for larger scale SUBs. Here we report a case of NS0 cell culture process transfer from 2000L stainless steel bioreactor (SST) to 2000L disposable bioreactor (SUB). Initial attempts in trying to grow the NS0 cells in the small scale 2D bags yielded non-satisfactory results, as growth was impacted by bag material type as well as by suppliers of the same bag material type. However, 3D bags of 50L and above proved to be supportive of the NS0 cell line growth. Even for cell lines that do not have growth issues in SUBs, surprising product quality difference between SUBs and traditional bench top glass bioreactors are still being observed, thus...
A scalable biomanufacturing platform is crucial to meet the anticipated demands for off-the-shelf ce...
In recent years, biologic drugs such as antibodies, biosimilars and fusion proteins have continued t...
Singe use bioreactors (SUBs) are becoming standard work horses in the biopharmaceutical industry. Th...
To accelerate cell culture process development, most companies have validated scale-down models of t...
Scale-down models are commonly used to execute process characterization studies, as well as to scree...
Allogeneic cell therapy products have enormous potential to treat a wide range of unmet medical need...
Since the inception of biopharmaceutical industry, scale up issues hampered the success of process t...
Cell culture scale up success depends on robust cell line, process, and equipment. Mixing characteri...
For cultivation of mammalian cells in biopharmaceutical research and manufacturing, single-use techn...
The first generation of single use bioreactors (SUBs) departed from conventional stirred tank biorea...
Product quality especially with respect to glycosylation is a critical product attribute which can h...
Two dimensional (2-D) cell culture technologies have proven inadequate for large scale manufacturing...
As part of efforts to develop a continuous processing platform for biologics manufacturing using sin...
The lack of an adequate scale-down model for the cell culture stages of legacy processes is an ongoi...
Quality by Design and Process Analytical Technology regulatory initiatives aim to achieve consistent...
A scalable biomanufacturing platform is crucial to meet the anticipated demands for off-the-shelf ce...
In recent years, biologic drugs such as antibodies, biosimilars and fusion proteins have continued t...
Singe use bioreactors (SUBs) are becoming standard work horses in the biopharmaceutical industry. Th...
To accelerate cell culture process development, most companies have validated scale-down models of t...
Scale-down models are commonly used to execute process characterization studies, as well as to scree...
Allogeneic cell therapy products have enormous potential to treat a wide range of unmet medical need...
Since the inception of biopharmaceutical industry, scale up issues hampered the success of process t...
Cell culture scale up success depends on robust cell line, process, and equipment. Mixing characteri...
For cultivation of mammalian cells in biopharmaceutical research and manufacturing, single-use techn...
The first generation of single use bioreactors (SUBs) departed from conventional stirred tank biorea...
Product quality especially with respect to glycosylation is a critical product attribute which can h...
Two dimensional (2-D) cell culture technologies have proven inadequate for large scale manufacturing...
As part of efforts to develop a continuous processing platform for biologics manufacturing using sin...
The lack of an adequate scale-down model for the cell culture stages of legacy processes is an ongoi...
Quality by Design and Process Analytical Technology regulatory initiatives aim to achieve consistent...
A scalable biomanufacturing platform is crucial to meet the anticipated demands for off-the-shelf ce...
In recent years, biologic drugs such as antibodies, biosimilars and fusion proteins have continued t...
Singe use bioreactors (SUBs) are becoming standard work horses in the biopharmaceutical industry. Th...